AEON Biopharma Inc Ordinary Shares - Class A AEON
News
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
AEON Biopharma Holds Meeting With FDA for Botox Biosimilar

